◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Brooks Laboratories Limited (BROOKS) Financial History

Name: Brooks Laboratories Limited (BROOKS) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Brooks Laboratories Limited (BROOKS) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 347 employees. Its market capitalization is roughly ₹2 billion. In the fiscal year ended 2026-03-31, BROOKS reported ₹854M in revenue and ₹246M in net income.

Brooks Laboratories Limited operates as a pharmaceutical manufacturer in India and internationally. It operates in two segments, Manufacturing and Trading.

Interactive charts & full statements →

BROOKS Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹854M	₹822M	₹790M	₹625M	—
Gross Profit	₹284M	₹228M	₹180M	₹13M	—
Operating Income (EBIT)	₹55M	₹65M	₹14M	(₹336M)	—
Net Income	₹246M	(₹100M)	(₹196M)	(₹209M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BROOKS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹230M	₹202M	₹166M	₹234M	₹255M	—
Gross Profit	₹103M	₹78M	₹76M	₹97M	₹96M	—
Operating Income (EBIT)	₹14M	₹3M	₹3M	₹21M	₹27M	—
Net Income	(₹18M)	₹15M	₹55M	₹80M	₹96M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BROOKS Free Cash Flow History

BROOKS Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹1.5B	₹1.2B	₹904M	₹1.1B	—
Total Liabilities	₹255M	₹256M	₹249M	₹356M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BROOKS viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

NECLIFE · Nectar Lifesciences Limited — ₹2 billion
2561 · VISEN Pharmaceuticals — HK$2 billion
2633 · Jacobson Pharma Corporation Limited — HK$2 billion
DMP · Dermapharm Holding SE — €2 billion
NATCAPSUQ · Natural Capsules Limited — ₹2 billion
BALPHARMA · Bal Pharma Limited — ₹2 billion
2348 · Dawnrays Pharmaceutical (Holdings) Limited — HK$1 billion
PPGN · PolyPeptide Group AG — CHF 1 billion

← BROL All “B” companies BROS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.